Anna Rivkin Global Lead, Fibrotic Diseases anna.rivkin@bms.com

Ildiko Antal Associate, Specialty ildiko.antal@bms.com

Mohamed Ragab Head, Immuno-Oncology/Oncology mohamed.h.ragab@bms.com

Timothy Fisher Global Lead, Immuno-Oncology/Oncology timothy.fisher@bms.com

Saryah Azmat Associate, Immuno-Oncology/Oncology saryah.azmat@bms.com

TECHNOLOGY TRANSACTIONS

Donnie McGrath Vice President, Search and Evaluation

Steve Yoder Head, Specialty stephen.yoder@bms.com

Martin Crook Global Lead, Cardiovascular martin.crook@bms.com

Mireia Gomez-Angelats Global Lead, Genetically Defined Diseases mireia.gomezangelats@bms.com

Stephen O’Keefe Global Lead, Immunoscience stephen.o’keefe@bms.com

SEARCH AND EVALUATION

Graham Brazier Vice President, Transactions

Matt Bunn Genomics, Bioinformatics and Clinical Imaging matt.bunn@bms.com

Michael Cucolo Drug Delivery and Formulation Sciences michael.cucolo@bms.com

Andrea Lauber Clinical Biomarkers and Pharmacodiagnostics andrea.lauber@bms.com

Karen Martell Biologics Discovery Platforms karen.martell@bms.com

Rob Penhallow Chemistry and ADME/Toxicology robert.penhallow@bms.com

Ping Cao Lead Discovery and Optimization and Protein Sciences and Structure ping.cao1@bms.com

For more information please visit: www.bms.com/partnering

5asd

- Paul Biondi, Senior Vice President Head, Business Development ”“Business development is a key component

of Bristol-Myers Squibb’s strategy and has strengthened and diversified our portfolio for long-term growth.

Working together for patients.

PARTNERING EXTERNAL INNOVATION

AND

5asd

BUSINESS DEVELOPMENT CONTACTS

OUR STRATEGIC FOCUS - 2016

Immuno-Oncology

• Focus on approaches that are direct acting on the immune system

- Novel immune checkpoint inhibitors and co-stimulatory agents

• Tumor intrinsic targets with demonstrated impact on anti-tumor immunity

• Tumor microenvironment

Oncology • Agents displaying synergy with immune

checkpoint inhibitors

• Established non-immunosuppressive mechanisms of action

• New approaches to validated cancer pathways

• Emerging areas of cancer biology

• Antibody drug conjugates (ADC) – novel targets and late preclinical/clinical-stage programs in areas of unmet medical need

• Out of Scope: Supportive care – BMS focuses on therapeutics

Immunoscience

• Assets with transformative potential in IBD, inflammatory arthritis, SLE/lupus nephritis and other autoimmune diseases with high unmet needs

• Out of Scope: allergy and asthma

Cardiovascular • Heart failure: acute, post-acute, HFrEF, HFpEF,

cardiomyopathy

• Highly validated targets addressing CV risk with clear specialty medicine development paths

• Out of Scope: LDL lowering, HDL raising, anticoagulant, hypertension

Fibrosis • Mechanisms that specifically block myofibroblast

activation/differentiation and profibrotic macrophage activation

• Targeted inhibition of TGF-beta and other developmental pathways

• Approaches and mechanisms that target matrix re-modeling, epithelial cell protection and repair

• New anti-fibrotic mechanisms with data supporting target validation and some safety understanding

• Non-invasive diagnostics and biomarkers

• Priority fibrotic diseases include: NASH, idiopathic pulmonary fibrosis, systemic sclerosis, IgA nephropathy

• Out of Scope: Eye fibrosis, wound healing, keloids, uterine (endometriosis)

Genetically Defined Diseases (GDD)

• Focus on monogenic diseases

• Clinical-stage opportunities in rare/orphan diseases targeting at or near mutant protein

• Special interest in clinical and preclinical opportunities targeting Duchenne Muscular Dystrophy, synuclein, Nav1.7, and familial cardiomyopathy (fCM – hypertrophic or dilated)

BRISTOL-MYERS SQUIBB DEVELOPMENT PORTFOLIO BY DISEASE AREA

Fibrotic Diseases Genetically Defined DiseasesImmuno-Oncology ImmunoscienceOncology Cardiovascular

YERVOY

Virology

OPDIVO

EMPLICITI

Prostvac

Urelumab (Anti-CD137)

Lirilumab (Anti-KIR)

Anti-LAG3

SPRYCEL ORENCIA

NULOJIX

Lulizumab (Anti-CD28)

Anti-CD40

Anti-CD40L

BTK Inhibitor

TYK2 Inhibitor

REYATAZ/EVOTAZ

DAKLINZA

SUNVEPRA 3

Beclabuvir (NS5B Non Nuc)

HIV Attachment Inhibitor*

HIV Maturation Inhibitor*

Anti-PD-L1

ELIQUIS

IKur Inhibitor

Factor XIa Inhibitor

PEG-FGF21 (1)

Galectin-3 Inhibitor

Anti-eTau

Anti-Myostatin

▶▶

▶▶

▶▶

▶

▶▶

▶▶

▶

▶

▶▶

Data as of December, 2015

BET Inhibitor▶

LPA1 Antagonist

PAR4 Antagonist

Ulocuplumab (Anti-CXCR4)

Anti-Fucosyl GM1

Anti-HER2

▶▶

▶

Mesothelin-ADC▶TECHNOLOGY INTERESTS

“ ”Developing cutting-edge science in our own labs and in collaboration with partners is critical to our ability to deliver transformational medicines to patients.- Giovanni Caforio, M.D. Chief Executive Officer

1 Approved in at least one major market (US, EU, JP)

2 In Phase III development or currently under regulatory review

3 Not approved in the U.S.

Marketed 1

Phase III 2

Phase II

Phase I

▶ Biologics

Small Molecules

Partnered or in Collaboration

DRUG PLATFORMS AND NOVEL TECHNOLOGIES

• Access to new chemical matter, including macrocycle and fragment libraries

• Novel antibody drug conjugate (ADC) technology

• Subcutaneous controlled release

• Oral delivery of millamolecules and macrocyclic peptides

• ADME/Toxicology: Modeling and prediction technology

• High throughput, label free screening and protein expression platform

• Emerging structure determination platform

• Non-invasive diagnostics and translational biomarkers

• Improved methods for single cell capture, and genomic characterization

• Scalable bioinformatics analysis capabilities using principles for reproducible research

Anti-GITR

Anti-CSF 1R

▶▶

Nitroxyl Donor

Pentraxin-2

PEG-FGF21(2)▶▶

Gene TherapyRNA Oligonucleotides

Small Molecules Biologics

Antibody Drug Conjugates Millamolecules

Drug Delivery Technology

* included in pending sale of HIV R&D assets to ViiV Healthcare